Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc logo

ARQT - Arcutis Biotherapeutics Inc Reuters News

$34.71 0.5  1.6%

Last Trade - 7:41pm

Sector
Healthcare
RiskRating
Speculative
Size
Mid Cap
Style
Sucker Stock
Market Cap £1.23bn
Enterprise Value £1.02bn
Revenue £n/a
Position in Universe 2303rd / 6715
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions ARQT Dividends
Reuters News
All News Reuters News Company Announcements
Arcutis to Present at the Cowen 41st Annual Health Care Conference
Thu 10:15pm News
BRIEF-Courtney Barton Joins Arcutis As Chief Compliance Officer And Chief Of Staff
18th Feb News
Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff
18th Feb News
Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
16th Feb News
Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock
16th Feb News
BUZZ-Arcutis Biotherapeutics: Falls on discounted share offering
3rd Feb News
BRIEF-Arcutis Biotherapeutics Announces Pricing Of Upsized Public Offering Of Common Stock
3rd Feb News
Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock
3rd Feb News
U.S. RESEARCH ROUNDUP-Argenx SE, Lithium Americas, Woodward
2nd Feb News
BRIEF-Arcutis Biotherapeutics Inc Files Prospectus Supplement Related To Offering Of $150 Million Of Shares Of Common Stock -SEC Filing
1st Feb News
BRIEF-Arcutis Biotherapeutics Announces Proposed Public Offering Of Common Stock
1st Feb News
Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock
1st Feb News
BRIEF-Arcutis Announces Positive Topline Results From Pivotal DERMIS-1 And -2 Phase 3 Trials Of Topical Roflumilast Cream In Plaque Psoriasis
1st Feb News
Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis
1st Feb News
BRIEF-Arcutis To Advance Topical Roflumilast Foam Into Phase 3 Development For The Treatment Of Seborrheic Dermatitis
20th Jan News
Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis
20th Jan News
BRIEF-Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (Arq-151) As A Potential Treatment For Atopic Dermatitis
13th Jan News
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis
13th Jan News
Matthew Moore Joins Arcutis as Chief Business Officer
11th Jan News
Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index
21st Dec '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.